NOTCH1
Neurogenic locus notch homolog protein 1
As of the edition of 20 October 2026, NOTCH1 (neurogenic locus notch homolog protein 1, UniProt P46531) has 2 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P46531
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 29
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Heart and blood vessels; Skin and connective tissue
- Registered trials of its drugs
- 13
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Crenigacestat | Stopped | Phase 2 | none listed |
| Brontictuzumab | Went quiet | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Eli Lilly | Route A |
| Bristol Myers Squibb | Route A |
| Mereo BioPharma | Route A |
The other 0 companies at NOTCH1
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at NOTCH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.